BeOne Medicines (ONC) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viatris (VTRS) has outperformed BeOne Medicines (ONC) over the past year, gaining 87.7% versus a gain of 12.4%. Over five years, VTRS leads with a +54.0% price change compared with +12.4% for ONC. BeOne Medicines is the larger company by market cap ($44.66 billion vs $22.50 billion), about 2.0 times the size.
On valuation, Viatris trades at a lower forward P/E (6.9x vs 35.9x for BeOne Medicines). Viatris pays a dividend yielding 2.45%, while BeOne Medicines does not currently pay one. BeOne Medicines converts more of its revenue into profit, with a net margin of 5.4% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | VTRS |
|---|---|---|
| Share price | $390.94 | $19.63 |
| Market cap | $44.66B | $22.50B |
| 1-day change | -2.19% | -1.26% |
| YTD return | +28.68% | +57.67% |
| 1-year return | +12.43% | +87.67% |
| 5-year return | +12.44% | +53.96% |
| P/E ratio (TTM) | 50.12 | — |
| Forward P/E | 35.93 | 6.94 |
| EPS (TTM) | $7.80 | $-0.53 |
| Dividend yield | 0.00% | 2.45% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $5.34B | $14.30B |
| Revenue growth (YoY) | +40.23% | -2.98% |
| Net income (latest FY) | $286.93M | $-3.51B |
| Gross margin | 87.49% | 35.06% |
| Operating margin | 8.37% | -18.62% |
| Net margin | 5.37% | -24.58% |
| 52-week high | $424.73 | $21.20 |
| 52-week low | $253.95 | $10.39 |
| Distance from 52-week high | -7.96% | -7.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +20.03% | +10.04% |
| Average volume | 392.74K | 9.11M |
| Shares outstanding | 105.38M | 1.15B |
| Employees | 12,000 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed ONC by 75.2 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.45% vs 0.00%).
- BeOne Medicines is more profitable, keeping 5.4 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs -2.98%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
ONC vs VTRS FAQ
Which is bigger, BeOne Medicines or Viatris?
BeOne Medicines (ONC) is larger, with a market capitalization of $44.66B compared with $22.50B for Viatris (VTRS).
Which stock has performed better over the past year, ONC or VTRS?
VTRS returned +87.67% over the past 12 months, compared with +12.43% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BeOne Medicines or Viatris?
Viatris pays a dividend yielding 2.45%, while BeOne Medicines does not currently pay a regular dividend.
Are BeOne Medicines and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.